ROG N Overzicht aandelen Roche Holding AG is actief in de farmaceutische en diagnostische sector in Europa, Noord-Amerika, Latijns-Amerika, Azië, Afrika, Australië en Oceanië. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Roche Holding AG Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Roche Holding Historische aandelenkoersen Huidige aandelenkoers CHF 5,523.26 52 Week Hoogtepunt CHF 6,580.00 52 Week Laag CHF 4,000.08 Bèta 0.14 1 maand verandering -5.32% 3 maanden verandering n/a 1 Jaar Verandering n/a 3 jaar verandering -34.41% 5 jaar verandering -10.35% Verandering sinds IPO 57.21%
Recent nieuws en updates
Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Jan 02
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions Dec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma Dec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma Dec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 05
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA Nov 25 Meer updates bekijken
Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Jan 02
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions Dec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma Dec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma Dec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 05
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA Nov 25
Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024 Nov 05
Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease Nov 02 Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials
Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study Oct 14
FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation Oct 11 Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Oct 02
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis Sep 14
FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Sep 13 Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis Sep 04
Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH Aug 27
Investor sentiment improves as stock rises 15% Aug 26
New minor risk - Earnings quality Aug 01
European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO) Jul 30
First half 2024 earnings released: EPS: CHF7.85 (vs CHF8.93 in 1H 2023) Jul 27
Roche Holding AG Raises Earnings Guidance for the Year 2024 Jul 25
BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche Jul 23 New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD) Jul 09
Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer Jul 04
Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024 Jun 26
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Jun 25
Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma Jun 20 Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma Jun 17
Investor sentiment improves as stock rises 18% Jun 12 Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant May 31
Roche Announces Management and Board Committee Changes May 28
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a) May 25
Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity May 18
Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer May 16
Roche Holding AG Provides Earnings Guidance for the Year 2024 Apr 24 FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer Apr 20
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab) Apr 17
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis Apr 12
Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors Mar 27 Roche Holding AG, Annual General Meeting, Mar 12, 2024 Mar 13
Upcoming dividend of CHF9.60 per share Mar 07
Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension Mar 05
Dividend of CHF9.60 announced Feb 23
Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Feb 17
Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need Feb 12
Full year 2023 earnings released: EPS: CHF14.39 (vs CHF15.53 in FY 2022) Feb 07
Dividend of CHF9.60 announced Feb 05
Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO) Feb 02 Roche Holding AG Proposes Dividend
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 30
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 29
European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types Jan 16
Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024 Dec 20
Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition Dec 12
Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A Dec 11 Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion. Dec 04
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 29
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 28
Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List Nov 18 Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types Nov 17
Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration Nov 09 Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy Nov 01
United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO) Oct 29
Roche Holding AG Confirms Outlook for 2023 Oct 19 Rendement voor aandeelhouders ROG N MX Pharmaceuticals MX Markt 7D 0% -0.9% -1.1% 1Y n/a -27.5% -14.4%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe ROG N presteerde ten opzichte van de MX Pharmaceuticals.
Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe ROG N presteerde ten opzichte van de MX markt.
Prijsvolatiliteit Is ROG N's price volatile compared to industry and market? ROG N volatility ROG N Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.3% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.1% 10% least volatile stocks in MX Market 2.8%
Stabiele aandelenkoers: De aandelenkoers van ROG N is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van ROG N in het afgelopen jaar te bepalen.
Over het bedrijf Opgericht Werknemers CEO Website 1896 103,605 Thomas Schinecker www.roche.com
Roche Holding AG is actief in de farmaceutische en diagnostische sector in Europa, Noord-Amerika, Latijns-Amerika, Azië, Afrika, Australië en Oceanië. Het bedrijf biedt farmaceutische producten aan in de therapeutische gebieden bloedarmoede, bloed- en vaste tumoren, dermatologie, hemofilie, ontstekings- en autoimmuunziekten, neurologische aandoeningen, oogheelkunde, ademhalingsaandoeningen en transplantatie. Het ontwikkelt ook producten voor verschillende therapeutische gebieden.
Meer tonen Roche Holding AG Samenvatting Hoe verhouden de winst en inkomsten van Roche Holding zich tot de beurswaarde? ROG N fundamentele statistieken Marktkapitalisatie Mex$4.68t Inkomsten(TTM ) Mex$241.23b Inkomsten(TTM ) Mex$1.38t
19.3x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) ROG N resultatenrekening (TTM ) Inkomsten CHF 60.58b Kosten van inkomsten CHF 15.43b Brutowinst CHF 45.16b Overige uitgaven CHF 34.54b Inkomsten CHF 10.62b
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
Jan 30, 2025
Winst per aandeel (EPS) 13.33 Brutomarge 74.54% Nettowinstmarge 17.53% Schuld/Eigen Vermogen Verhouding 104.8%
Hoe presteerde ROG N op de lange termijn?
Bekijk historische prestaties en vergelijking Dividenden
3.7% Huidig dividendrendement
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/04 10:51 Aandelenkoers aan het einde van de dag 2024/12/20 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Roche Holding AG wordt gevolgd door 57 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Kamla Singh AlphaValue John Staszak Argus Research Company Gerhard Schwarz Baader Helvea Equity Research
Toon 54 meer analisten 
